Why Oncology Can Be a Tough Sell in Maine

Mike Hennessy
Published: Wednesday, Sep 20, 2017
Mike Hennessy

OncLive Chairman,

Mike Hennessy
Chimeric antigen receptor (CAR) T-cell therapy may soon hit the market, and numerous cancer care centers are poised to offer this for what may be the first FDA-approved indication: relapsed/refractory B-cell acute lymphoblastic leukemia. The promise of CAR T cells along with the potentially severe adverse events (AEs) have been well documented. One of those AEs may be financial toxicity. Consider a potential price tag as high as 0,000! Advocates argue that the ability to give the gift of a cancer-free life to a child or young adult may well be worth the money.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Publication Bottom Border
Border Publication
x